Why Influencers Use the FDA to Bash Research Peptides

The FDA approval process is often held up as the gold standard for deciding what is safe and what is not, and the logic sounds reasonable on the surface because a drug without FDA approval has not gone through rigorous testing, and a drug that has gone through that process has been vetted by an independent government agency.

Both of those assumptions are wrong in ways that matter.

To understand why, you need to understand how the FDA actually pays for its drug review process. There is something called PDUFA, the Prescription Drug User Fee Act, which is the law that allows pharmaceutical companies to pay the FDA directly to have their drug applications reviewed. As of fiscal year 2024, that fee is $4,198,000 per application. And those fees do not just supplement the FDA's budget. They fund approximately 65% of the entire drug review budget for the centers responsible for human drug approval.

The companies being regulated are paying for more than half of their own regulation. That is not a conspiracy theory. That is a published budget line.

Now think about what that structure does over time. The FDA does not get its review funding from taxpayers in a way that would make it independent of industry. It gets that funding from the applicants themselves, which means the volume of drug approvals and the fees attached to them are what keep the lights on. That creates a pressure, not necessarily explicit, but structural, to keep the pipeline moving.

Then consider what happens when FDA officials leave the agency. A 2018 analysis in Science found that 62% of FDA medical officers who left between 2006 and 2019 went directly to work for the pharmaceutical industry. The commissioner who served from 2017 to 2019 left and joined Pfizer's board of directors that same year. The people setting the standards and making the decisions are often, within months of leaving, working for the companies those decisions affected.

And pharmaceutical companies spend $374 million per year on federal lobbying, which works out to roughly three registered lobbyists for every single member of Congress. That is the highest lobbying spend of any industry in the country.

This is the system that gets cited as the authority on what is safe.

So when someone tells you that a research peptide is suspect because it lacks FDA approval, what they are functionally saying is that it has not been submitted to a process funded by the companies who profit from drugs, staffed by people who often leave for those same companies, and surrounded by more lobbying pressure than any other industry in Washington. That is what the approval stamp represents structurally, whatever it may represent scientifically in individual cases.

Now here is where peptides specifically fit into this, and why they will never carry an FDA approval regardless of what the research shows.

The cost to bring a new drug through FDA approval from development to market runs a median of $985 million in capitalized investment, according to a 2020 analysis published in JAMA Internal Medicine. That is nearly a billion dollars. No company spends that unless it can patent the drug and protect its return on that investment through market exclusivity.

Peptides are naturally occurring sequences of amino acids. You cannot patent a naturally occurring compound. There is no mechanism to recover a billion dollar investment if any competitor can synthesize and sell the same sequence the day your approval goes through. So no pharmaceutical company will ever submit a peptide for FDA approval, not because the research is insufficient, but because the business case does not exist.

The approval process was not designed for compounds like these. It was designed for novel patentable molecules where the company funding the application can later charge monopoly prices during the exclusivity window and recover its costs. Peptides do not fit that model, so they do not enter that pipeline, which means they will remain unapproved indefinitely regardless of what the research accumulates.

This is the actual reason research peptides do not carry FDA approval. Not safety data. Not science. Patent law and return on investment.

Which brings us to the specific behavior the video was pointing at, and why it is worth naming clearly. There is a pattern where people who are openly skeptical of government institutions, and who position themselves as being against the system, will turn around and use FDA approval as an authority when it serves their commercial interest. They sell peptides sourced from compounding pharmacies, they use the FDA's unapproval of research chemicals as a reason to distrust them, and they ignore the entire structural explanation for why that unapproval exists.

A compounding pharmacy operates under a different regulatory pathway than research chemical suppliers, but it does not mean the compounded peptide has been reviewed for safety or efficacy by the FDA either. Compounding is not FDA approval. The distinction being drawn is often less about safety and more about which business model the person speaking is currently running.

You cannot use a corrupt institution as your shield when it benefits your revenue and then reject that same institution when it costs you something. The intellectual position requires choosing one.

The deeper issue is that FDA approval has become a proxy for safety in public conversation, and that proxy breaks down the moment you look at the financial architecture underneath it. The agency has done real work and approved drugs that genuinely help people, and the approval process does generate scientific review that matters in many cases. But the stamp itself is not a neutral signal. It is a signal that a company with hundreds of millions of dollars found it profitable to submit. When that condition is not met, the absence of the stamp tells you almost nothing about the underlying science.

That distinction is what gets erased when someone with a financial interest in one peptide channel over another uses FDA approval as their argument.

---

References

1. FDA PDUFA Fee Schedule — Federal Register (published annually). FY 2024 application fee: $4,198,000.
2. FDA Budget Justification to Congress — PDUFA user fees fund approximately 65% of CDER/CBER human drug review budget.
3. Piller, C. (2018). "Is FDA's revolving door open too wide?" Science. Found 62% of FDA medical officers who left between 2006-2019 went to work for pharmaceutical industry.
4. OpenSecrets.org — Center for Responsive Politics. Pharmaceutical/health products industry spent $374 million on federal lobbying in 2023, #1 ranked industry. Approximately 1,500-1,800 registered lobbyists (roughly 3:1 ratio to members of Congress).
5. Scott Gottlieb served as FDA Commissioner 2017-2019, joined Pfizer board of directors in 2019.
6. Wouters, O.J., McKee, M., Luyten, J. (2020). "Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018." JAMA Internal Medicine. Median capitalized cost: $985 million per drug.

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness